



Cardiovascular Team Cases

USE OF CANGRELOR AS A BRIDGE TO GYNECOLOGICAL SURGERY IN A CARDIAC PATIENT WITH RECENT CARDIAC STENT PLACEMENT FOR NSTEMI

Poster Contributions

Poster Hall, Hall A/B

Saturday, March 10, 2018, 10:00 a.m.-10:45 a.m.

Session Title: Nontraditional Use of Antiplatelet Agents: Team Based Care

Presentation Number: 1107-113

Authors: *Simon Leung, Margaretta Kearson, Wenhui Zhou, Brittany Ball, Memorial Regional Hospital, Hollywood, FL, USA*

Background: Use of intravenous (IV) cangrelor has been confined to interventional cardiology in the cardiac catheterization area.^{1,2} However, information on IV cangrelor use outside of this setting is limited.^{2,3} We report a case of using IV cangrelor in replacement of dual antiplatelet therapy (DAPT) as a bridge to gynecological surgery in a cardiac patient.

Case: A 55 year old female with a recent cardiac stent placement for NSTEMI on 6/28/2017 where she was prescribed aspirin and ticagrelor presented for gynecological surgery. On 7/5/2017, she was hospitalized for vaginal bleeding and clots and was subsequently diagnosed with endometrial cancer. The decision was to have her undergoing a total abdominal hysterectomy. Cardiology recommended stopping DAPT 3 days before surgery on 8/30/2017 and initiating IV cangrelor infusion when P2Y12 reaction returned to 160 PRU or above. IV cangrelor was initiated on 8/28/2017 and was stopped 9 hours before surgical incision. Patient tolerated surgery with minimal blood loss. Reloading ticagrelor was initiated 18 hours after surgery.

Decision-making: My role was ensuring the availability of IV cangrelor before surgery; team role was managing the patient during the hospital stay; innovation was using IV cangrelor infusion outside of regular practice setting; practice model suggested using IV cangrelor as a bridge to noncardiac surgery in high risk cardiac patients.

Conclusion: Careful planning, including timing to stop DAPT, initiate cangrelor and reload ticagrelor, was the key to achieve positive patient outcomes.

References/Resources: Bhatt DL, Stone GW, Mahaffey KW, et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. *N Engl J Med.* 2013;368:1303-13.

Vaduganathan M, Qamar A, Singh A, et al. Cangrelor use since FDA approval: a single-center, real-world experience at a tertiary care hospital. *J Am Coll Cardiol.* 2017;69:463-4. Angiolillo DJ, Firstenberg MS, Price MJ, et al. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery. *JAMA.* 2012;307:265-74